OverviewSuggest Edit

Roivant Sciences is a tech-enabled healthcare company focused on completing the development of late-stage drug candidates with the potential to improve the lives of patients and their families. It also develops healthcare technologies through subsidiaries such as Datavant, which helps healthcare institutions share and aggregate data, and Lokavant, which integrates clinical trial data sources to identify and mitigate risks in drug development.

TypePrivate
Founded2014
HQNew York, US
Websiteroivant.com

Latest Updates

Employees (est.) (Sept 2020)246(-1%)
Job Openings12
Cybersecurity ratingAMore

Key People/Management at Roivant Sciences

Vivek Ramaswamy

Vivek Ramaswamy

Founder & CEO
Mayukh Sukhatme

Mayukh Sukhatme

Chief Investment Officer & President
Frank Torti

Frank Torti

Vant Chair
Jo Chen

Jo Chen

General Counsel
Benjamin Zimmer

Benjamin Zimmer

President
Matthew Gline

Matthew Gline

CFO
Show more

Roivant Sciences Office Locations

Roivant Sciences has offices in New York and Basel
New York, US (HQ)
151 W 42nd St 15th Floor
Basel, CH
Viaduktstrasse 8
Show all (2)

Roivant Sciences Financials and Metrics

Summary Metrics

Founding Date

2014

Roivant Sciences total Funding

$1.9 b

Roivant Sciences latest funding size

$200 m

Time since last funding

2 years ago

Roivant Sciences investors

Roivant Sciences's latest funding round in November 2018 was reported to be $200 m. In total, Roivant Sciences has raised $1.9 b. Roivant Sciences's latest valuation is reported to be $7 b.
View all funding rounds

Roivant Sciences Revenue

Market valuation

7.0b
Show all financial metrics

Roivant Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Dermavant Sciences

Roivant Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Roivant Sciences Online and Social Media Presence

Embed Graph

Roivant Sciences News and Updates

Roivant Sciences Continues its Partnership With BaseLaunch for Phase II

BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that Roivant Sciences has joined as the third partner of BaseLaunch Phase II, the next phase in BaseLaunch's company building activities. Roivant Sciences has already been a partner in the first Phase of Bas…

Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200

Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of US$667.5M inc…

Roivant Sciences Announces $200 Million Investment Round

Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors comprise a majority of the round. All existing institutional shareholders in Roivant are also parti…

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

Nabriva Therapeutics and Roivant Sciences enter into license agreement to develop and commercialize lefamulin in greater china* nabriva therapeutics - lefamulin has completed phase 3 trial for treatment of adults with moderate to severe community-acquired bacterial pneumonia

Roivant Sciences Blogs

Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan

JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan Dermavant to receive an upfront payment of $60 million, additional pre-commercial milestone payments of up to $53 million, and sales royalties Tapinarof is …

Axovant Announces Positive 12-Month Data on AXO-LENTI-PD and Provides Updates Across Gene Therapy Pipeline Programs

NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its Park…

Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring

Lokavant has entered into multi-year enterprise license agreement with Parexel BASEL, Switzerland and NEW YORK, January 13, 2020 /PRNewswire/ — Roivant Sciences today unveiled Lokavant, a technology company whose mission is to ensure that no clinical trial fails due to operational error. By integrat…

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline

Altavant plans to develop OSP-101 for the treatment of bronchiolitis obliterans syndrome, the leading cause of morbidity and mortality in post-lung transplant patients Cary, NC; Basel, Switzerland and Wayne, PA – January 8, 2020 – Altavant Sciences, a clinical-stage biopharmaceutical company focused…

Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen NEW Y…

Roivant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK and BASEL, Switzerland, Jan. 8, 2020 — Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent developments and future directions for the business at the 38th Annual J.P. Morgan Healthcare Conference in San Fr…
Show more

Roivant Sciences Frequently Asked Questions

  • When was Roivant Sciences founded?

    Roivant Sciences was founded in 2014.

  • Who are Roivant Sciences key executives?

    Roivant Sciences's key executives are Vivek Ramaswamy, Mayukh Sukhatme and Frank Torti.

  • How many employees does Roivant Sciences have?

    Roivant Sciences has 246 employees.

  • Who are Roivant Sciences competitors?

    Competitors of Roivant Sciences include Samumed, Ironwood Pharmaceuticals and SciClone Pharmaceuticals.

  • Where is Roivant Sciences headquarters?

    Roivant Sciences headquarters is located at 151 W 42nd St 15th Floor, New York.

  • Where are Roivant Sciences offices?

    Roivant Sciences has offices in New York and Basel.

  • How many offices does Roivant Sciences have?

    Roivant Sciences has 2 offices.